A postbiotic — a new product that holds up in Excel and on the shelf

First, the million-dollar question: is the market growing at all?

The short answer: yes. MarketsandMarkets, market.us, DataM Intelligence and Precedence Research forecast growth of around 9% a year for the postbiotics market (a range of 8.9-9.6%). At that pace, the market's value more than doubles within a decade. These are forecasts from commercial research firms whose reports cite one another — so treat them not as scientific certainty but as a consistent, repeated signal of direction.

The largest application segment is dietary supplements — about 43% of the market per market.us. Then come functional food and drinks, cosmetics and pet food. North America and Europe set the tone, while Asia grows fastest. Interestingly, about 35% of consumers don't yet know the word “postbiotic” — that's not a flaw but a hidden gift: the association with probiotics and prebiotics is obvious, and a brand that goes deep on the topic now becomes the consumer's point of reference.

What exactly is a postbiotic

Postbiotics are the youngest child in the biotic family. They only received an official definition in 2021, when ISAPP (the International Scientific Association for Probiotics and Prebiotics) published a consensus in Nature Reviews Gastroenterology & Hepatology. Under it, a postbiotic is a preparation of inanimate microorganisms or their components that confers a health benefit. These are not live cultures, but carefully prepared microbial biomass together with its active elements.

One detail matters for implementation: a postbiotic must contain inanimate cells or their components, not metabolites alone. Yarrowia lipolytica yeast biomass fits perfectly here. The definition's young age works in its favor twice over: the category is already scientifically settled (firm ground for the regulatory department), while commercially it's early enough that there's still room to plant a flag.

Why yeast specifically, and not another probiotic from the fridge

This is the part production and logistics will love. A postbiotic contains no live microorganisms, so you don't have to keep bacteria alive through production, storage and six months on the shelf. As a group, postbiotics can be markedly more stable than many live probiotics (ISAPP confirms this): good resistance to processing, a long shelf life, usually no cold-chain requirement — the exact parameters depend on the formulation. For a buyer that means fewer complaints and losses; for a project manager, a simpler formula.

The market shows that yeast postbiotics are no experiment. The best-documented example is fermented Saccharomyces cerevisiae yeast — over fifteen published studies and, per Innova data, the postbiotic ingredient present in the largest number of supplements worldwide. That's not proof of Yarrowia's efficacy specifically, but proof of something equally valuable: the market knows, accepts and readily buys yeast postbiotics as a category. Yarrowia therefore enters ground that's already familiar.

What we actually know about Yarrowia, no sugar-coating

Yarrowia lipolytica biomass is produced by propagating the yeast and deactivating its cells. It contains cell-wall components, exceptionally rich in beta-glucans and mannans. Yeast beta-glucans (with a 1,3/1,6 structure) are among the best-studied compounds with immunomodulatory action — there are even human clinical trials (on beta-glucan from Saccharomyces) suggesting immune support, e.g. a milder course of upper respiratory tract infections. For Yarrowia itself, a peer-reviewed review in Applied Microbiology and Biotechnology (2021) describes its health and nutritional properties; mannans are studied mainly for supporting gut microflora balance.

The honest conclusion: we have a well-studied ingredient class and promising data for Yarrowia itself (mainly from animal and in-vitro studies). That builds a buyer's trust more than the prettiest slogan.

The argument that finally makes legal smile

Many great product ideas die quietly because the ingredient has no regulated status. With Yarrowia it's the opposite. Yarrowia lipolytica yeast biomass is authorized in the EU as novel food (Novel Food) under Commission Implementing Regulation 2019/760 of May 2019, issued after a positive EFSA safety opinion. Novel Food status confirms the ingredient is safe under defined conditions of use.

There's one more thing that helps when planning a portfolio: the scope of permitted uses is being expanded by the European Commission, not narrowed. Successive acts — including Regulation 2024/2044 — have extended its use to, among others, meal replacements for weight control in adults. You're investing in an ingredient whose space of legal uses grows over time — a single successful product can be the first of a whole series.

Pulling it together from the perspective of whoever signs off on the project: on the opportunity side there's a growing market, a young category with room for positioning, and a consumer still learning the topic. On the risk side — where our sleepless nights usually live — there's an unusual amount of good news: EFSA-confirmed safety, a regulated and expanding EU status, good technological stability, and grounding in a well-studied ingredient class. That's the setup every sensible buyer and every project manager who likes to sleep is looking for. We write more about the technology itself in our post on Yarrowia lipolytica postbiotics and on the functional food page.

Frequently asked questions